Engineered immune cells take on Hard-to-Treat myeloma

NCT ID NCT07477912

Recruiting now Disease control Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a treatment called anti BCMA CAR-T cell therapy for adults with multiple myeloma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and kill myeloma cells. The trial aims to see if it is safe and how well it works in 30 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti BCMA CAR-T cells
What this could lead to: If successful, this could offer a new treatment option for patients with multiple myeloma that has not responded to other therapies.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to everyone. CAR-T therapy can cause severe side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA REFRACTORY

Contacts and locations

Locations

State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology
RECRUITING

Minsk, 220087, Belarus

More trials for these conditions

Other studies related to the condition(s) this trial covers.